Thanks to visit codestin.com
Credit goes to link.springer.com

Skip to main content
Springer Nature Link
Log in

Metformin and gestational diabetes

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Pregnancy increases requirements for insulin secretion, increasing insulin resistance and demands on pancreatic β cells, promoting development of gestational diabetes (GD), particularly in women with preexisting insulin resistance, commonly in women with polycystic ovary syndrome. Preliminary studies suggest that metformin may have the unique potential to prevent the development of GD. We postulate that interventions that reduce insulin resistance and lower requirements for endogenous insulin secretion can preserve β-cell function and prevent the development of type 2 diabetes mellitus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+
from £29.99 /Month
  • Starting from 10 chapters or articles per month
  • Access and download chapters and articles from more than 300k books and 2,500 journals
  • Cancel anytime
View plans

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Explore related subjects

Discover the latest articles, books and news in related subjects, suggested using machine learning.

References and Recommended Reading

  1. Homko C, Sivan E, Chen X, et al.: Insulin secretion during and after pregnancy in patients with gestational diabetes mellitus. J Clin Endocrinol Metab 2001, 86:568–573.

    Article  PubMed  CAS  Google Scholar 

  2. Glueck CJ, Wang P, Kobayashi S, et al.: Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002, 77:520–525. The first detailed study which revealed that metformin reduced the development of GD in women with PCOS.

    Article  PubMed  CAS  Google Scholar 

  3. Butte NF: Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. Am J Clin Nutr 2000, 71:1256S-1261S.

    PubMed  CAS  Google Scholar 

  4. Xiang AH, Peters RK, Trigo E, et al.: Multiple metabolic defects during late pregnancy in women at high risk for type 2 diabetes. Diabetes 1999, 48:848–854.

    Article  PubMed  CAS  Google Scholar 

  5. Buchanan TA, Xiang AH, Peters RK, et al.: Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes 2000, 49:782–788.

    Article  PubMed  CAS  Google Scholar 

  6. Buchanan TA: Pancreatic B-cell defects in gestational diabetes: implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab 2001, 86:989–993. An elegant description of metabolic defects during pregnancy in women at high risk for type 2 DM.

    Article  PubMed  CAS  Google Scholar 

  7. Coustan DR: Gestational diabetes. In Diabetes in America. Edited by Harris MI, et al. Bethesda, MD: National Institutes of Health; 1995:703–717.

    Google Scholar 

  8. Engelgau MM, Herman WH, Smith PJ, et al.: The epidemiology of diabetes and pregnancy in the U.S., 1988. Diabetes Care 1995, 18:1029–1033.

    Article  PubMed  CAS  Google Scholar 

  9. Damm P: Gestational diabetes mellitus and subsequent development of overt diabetes mellitus. Dan Med Bull 1998, 45:495–509.

    PubMed  CAS  Google Scholar 

  10. Lup VR, Stys SJ: Recurrence of gestational diabetes in subsequent pregnancies. In Gestational Diabetes. Edited by Weiss PA, Coustan DR. Vienna, Austria: Springer-Verlag; 1988:123–126.

    Google Scholar 

  11. Gestational diabetes mellitus. American Diabetes Association [no authors listed]. Diabetes Care 2003, 26(suppl 1):5103–5105.mExcellent summary position paper of the American Diabetes Association.

  12. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 30, September 2001 (replaces Technical Bulletin Number 200, December, 1994). Gestational diabetes [no authors listed]. Obstet Gynecol 2001, 98:525–538.Excellent summary position paper of the American College of Obstetricians and Gynecologists.

  13. Melzer S, Leiter L, Daneman D, et al.: Clinical practice guideline for the management of diabetes in Canada. CMAJ 1998, 159(suppl 8):S1-S29.

    Google Scholar 

  14. Metzger BE, Coustan DR: Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes. The organizing committee. Diabetes Care 1998, 21(suppl 2):B161-B167.

    PubMed  Google Scholar 

  15. Hanna FW, Peters JR: Screening for gestational diabetes; past, present, and future. Diabet Med 2002, 19:351–358.

    Article  PubMed  CAS  Google Scholar 

  16. Aberg A, Rydhstroem H, Frid A: Impaired glucose tolerance associated with adverse pregnancy outcome: a populationbased study in southern Sweden. Am J Obstet Gynecol 2001, 184:77–83.

    Article  PubMed  CAS  Google Scholar 

  17. Buchanan TA, Kjos SL: Counterpoint: glucose monitoring in gestational diabetes. Lots of heat, not much light. Diabetes Care 2003, 26:948–949. Decisive review of the strength of the evidence relating glucose monitoring to outcome.

    Article  PubMed  Google Scholar 

  18. Sermer M, Naylor CD, Gare DJ, et al.: Impact of increasing carbohydrate intolerance on maternal-fetal outcomes in 3637 women without gestational diabetes. The Toronto Tri-Hospital Gestational Diabetes Project. Am J Obstet Gynecol 1995, 173:146–156.

    Article  PubMed  CAS  Google Scholar 

  19. Hunter DJS, Kierse MJNC: Gestational Diabetes in effective care. In Pregnancy and Childbirth. Edited by Enkin M, Kierse M. Oxford: Oxford University Press; 1989:403–410.

    Google Scholar 

  20. Ouzilleau C, Roy M-A, Leblanc L, et al.: An observational study comparing 2-hour 75-g oral glucose tolerance with fasting plasma glucose in pregnant women: both poorly predictive of birth weight. CMAJ 2003, 168:403–409. Large, well-done observational study revealing that glucose levels during pregnancy are only weakly predictive of birth weight.

    PubMed  Google Scholar 

  21. The hyperglycemia and adverse pregnancy (HAPO) study. HAPO Study Cooperative Research Group [no authors listed]. Int J Gyn Obstet 2002, 78:69–77. Important summary of forthcoming study that may answer many current controversies regarding GD.

    Article  Google Scholar 

  22. Yang X, Hsu-Hage B, Zhang H, et al.: Women with impaired glucose tolerance during pregnancy have significantly poor pregnancy outcomes. Diabetes Care 2002, 25:1619–1624.

    Article  PubMed  Google Scholar 

  23. Lao TT, Wong KY: Perinatal outcome in large-for-gestationalage infants. Is it influenced by gestational impaired glucose tolerance? J Reprod Med 2002, 47:497–502.

    PubMed  Google Scholar 

  24. Sheffield JS, Butler-Koster EL, Casey BM, et al.: Maternal diabetes mellitus and infant malformations. Obstet Gynecol 2002, 100:925–930. Elegant study of maternal DM and its relationship to infant malformations.

    Article  PubMed  Google Scholar 

  25. Farrell T, Neale L, Cundy T: Congenital abnormalities in the offspring of women with type 1, type 2 and gestational diabetes. Diabet Med 2002, 19:322–326.

    Article  PubMed  CAS  Google Scholar 

  26. Jensen DM, Sorensen B, Feilberg-Jorgensen N, et al.: Maternal and perinatal outcomes in 143 Danish women with gestational diabetes mellitus and 143 controls with a similar risk profile. Diabet Med 2000, 17:281–286.

    Article  PubMed  CAS  Google Scholar 

  27. Hod M, Bar J, Peled Y, et al.: Antepartum management protocol. Timing and mode of delivery in gestational diabetes. Diabetes Care 1998, 21(suppl 2):B113-B117.

    PubMed  Google Scholar 

  28. Persson B, Hanson U: Neonatal morbidities in gestational diabetes mellitus. Diabetes Care 1998, 21(suppl 2):B79-B84.

    PubMed  Google Scholar 

  29. Moore LL, Singer MR, Bradlee ML, et al.: A prospective study of the risk of congenital defects associated with maternal obesity and diabetes mellitus. Epidemiology 2000, 11:689–694. Excellent epidemiologic study of the relationship of maternal obesity and DM to congenital defects.

    Article  PubMed  CAS  Google Scholar 

  30. Svare JA, Hansen BB, Molsted-Pedersen L: Perinatal complications in women with gestational diabetes mellitus. Acta Obstet Gynecol Scand 2001, 80:899–904.

    Article  PubMed  CAS  Google Scholar 

  31. Oral E, Cagdas A, Gezer A, et al.: Perinatal and maternal outcomes of fetal macrosomia. Eur J Obstet Gynecol Reprod Biol 2001, 99:167–171.

    Article  PubMed  CAS  Google Scholar 

  32. Ibanez L, Valls C, Ferrer A, et al.: Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 2001, 86:3595–3598. Innovative study of insulin sensitization at the inception of adolescent anovulatory hyperandrogenism.

    Article  PubMed  CAS  Google Scholar 

  33. Kousta E, Cela E, Lawrence N, et al.: The prevalence of polycystic ovaries in women with a history of gestational diabetes. Clin Endocrinol (Oxf) 2000, 53:501–507.

    Article  CAS  Google Scholar 

  34. Kowalska I, Kinalski M, Straczkowski M, et al.: Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome. Eur J Endocrinol 2001, 144:509–515.

    Article  PubMed  CAS  Google Scholar 

  35. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999, 84:165–169.

    Article  PubMed  CAS  Google Scholar 

  36. Nardo LG, Rai R: Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects. Gynecol Endocrinol 2001, 15:373–380.

    PubMed  CAS  Google Scholar 

  37. Norman RJ, Masters L, Milner CR, et al.: Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001, 16:1995–1998.

    Article  PubMed  CAS  Google Scholar 

  38. Ehrmann DA, Barnes RB, Rosenfield RL, et al.: Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999, 22:141–146.

    Article  PubMed  CAS  Google Scholar 

  39. Korhonen S, Hippelainem M, Niskanen L, et al.: Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population based study. Am J Ob Gyn 2001, 184:289–296.

    Article  CAS  Google Scholar 

  40. Conn JJ, Jacobs HS, Conway GS: The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2000, 52:81–86. Details that many women with type 2 DM can be shown to have polycystic ovaries.

    Article  CAS  Google Scholar 

  41. Peppard HR, Marfori J, Iuorno MJ, Nestler JE: Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care 2001, 24:1050–1052. Illustrates that many women with type 2 DM have previously undiagnosed PCOS.

    Article  PubMed  CAS  Google Scholar 

  42. Solomon CG, Hu FB, Dunaif A, et al.: Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA 2001, 286:2421–2426.

    Article  PubMed  CAS  Google Scholar 

  43. Hu FB, Manson JE, Stampfer MJ, et al.: Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001, 345:790–797.

    Article  PubMed  CAS  Google Scholar 

  44. Lillioja S, Mott DM, Spraul M, et al.: Insulin resistance and insulin secretory dysfunction as precursors of non-insulindependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993, 329:1988–1992.

    Article  PubMed  CAS  Google Scholar 

  45. Polderman KH, Gooren LJ, Asscheman H, et al.: Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 1994, 79:265–271.

    Article  PubMed  CAS  Google Scholar 

  46. Fleming R, Hopkinson ZE, Wallace AM, et al.: Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002, 87:569–574. The largest double-blind placebo-controlled trial currently extant.

    Article  PubMed  CAS  Google Scholar 

  47. Moghetti P, Castello R, Negri C, et al.: Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000, 85:139–146.

    Article  PubMed  CAS  Google Scholar 

  48. Glueck CJ, Phillips H, Cameron D, et al.: Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001, 75:46–52. The first pilot study of continuation of metformin throughout pregnancy in women with PCOS, revealing safety and reduction of first-trimester SABs.

    Article  PubMed  CAS  Google Scholar 

  49. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L: Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002, 17:2858–2864. The largest systematic observational study to date, revealing that metformin reduced first-trimester SABs, reduced GD, had no effect on neonatal birth weight or length, and was not teratogenic.

    Article  PubMed  CAS  Google Scholar 

  50. O'Sullivan JB, Mahan CM, Charles D, Dandrow RV: Screening criteria for high-risk gestational diabetic patients. Am J Obstet Gynecol 1973, 116:895–900.

    PubMed  Google Scholar 

  51. Glueck CJ, Goldenberg N, Streicher P, Wang P: The contentious nature of gestational diabetes: diet, insulin, glyburide, and metformin. Expert Opin Pharmacother 2002, 3:1557–1568.

    Article  PubMed  CAS  Google Scholar 

  52. Glueck CJ, Koyabashi S, Sieve-Smith L, Wang P: Primary prevention of type 2 diabetes? Metformin reduces gestational diabetes four-fold in women with polycystic ovary syndrome [abstract]. Circulation 2002, 106:3673.

    Google Scholar 

  53. Bornovali S, Pranikoff T, Glueck CJ, et al.: Metformin continued throughout pregnancy in women with polycystic ovary syndrome is not associated with an increased prevalence of pre-eclampsia. J Invest Med 2003, 51(suppl 2):S378.

    Google Scholar 

  54. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al.: Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87:524–529. Confirmatory evidence that metformin reduces first-trimester SABs and does not appear to be teratogenic.

    Article  PubMed  CAS  Google Scholar 

  55. Goldenberg N, Glueck CJ, Smith L, Wang P: Metformin during pregnancy in women with polycystic ovary syndrome reduces development of gestational diabetes and protects against fetal macrosomia [abstract]. J Invest Med 2003, 51(suppl 2):S384.

    Google Scholar 

  56. Goldenberg N, Glueck CJ, Kobayashi S, et al.: Primary prevention of type 2 diabetes? Metformin reduces gestational diabetes four fold in women with polycystic ovary syndrome [abstract]. J Invest Med 2002, 50:291A.

    Google Scholar 

  57. Coetzee EJ, Jackson WP: The management of non-insulindependent diabetes during pregnancy. Diabetes Res Clin Pract 1985, 1:281–287.

    Article  PubMed  Google Scholar 

  58. Coetzee EJ, Jackson WP: Oral hypoglycaemics in the first trimester and fetal outcome. S Afr Med J 1984, 65:635–637.

    PubMed  CAS  Google Scholar 

  59. Coetzee EJ, Jackson WP: Pregnancy in established non-insulin-dependent diabetics. A five-and-a-half year study at Groote Schuur Hospital. S Afr Med J 1980, 58:795–802.

    PubMed  CAS  Google Scholar 

  60. Coetzee EJ, Jackson WP: Metformin in management of pregnant insulin-independent diabetics. Diabetologia 1979, 16:241–245.

    Article  PubMed  CAS  Google Scholar 

  61. Jackson WP, Coetzee EJ: Side effects of metformin. S Afr Med J 1979, 56:1113–1114.

    PubMed  CAS  Google Scholar 

  62. Heard MJ, Pierce A, Carson SA, Buster JE: Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. Fertil Steril 2002, 77:669–673. Elegant study documenting effectiveness of metformin in ovulation induction and safety during pregnancy.

    Article  PubMed  Google Scholar 

  63. Morrison JA, Laskarzewski P, deGroot I, et al.: Diagnostic ramifications of repeated cholesterol and triglyceride measurements in children: regression toward the mean in a pediatric population. Pediatrics 1979, 64:197–201.

    PubMed  CAS  Google Scholar 

  64. Denno KM, Sadler TW: Effects of the biguanide class of oral hypoglycemic agents on mouse embryogenesis. Teratology 1994, 49:260–266.

    Article  PubMed  CAS  Google Scholar 

  65. Hellmuth E, Damm P, Molsted-Pedersen L: Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med 2000, 17:507–511.

    Article  PubMed  CAS  Google Scholar 

  66. Buchanan TA, Xiang AH, Peters RK, et al.: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in highrisk hispanic women. Diabetes 2002, 51:2796–2803. Seminal study suggesting that troglitazone may be useful in the primary prevention of type 2 DM.

    Article  PubMed  CAS  Google Scholar 

  67. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Diabetes prevention program research group: reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403. Innovative approach to the primary prevention of type 2 DM.

    Article  PubMed  CAS  Google Scholar 

  68. Tuomilehto J, Lindstrom J, Eriksson JG, et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343–1350. Important documentation of the importance of major lifestyle changes in the primary prevention of type 2 DM.

    Article  PubMed  CAS  Google Scholar 

  69. Freemark M, Bursey D: The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001, 107:E55.

    Article  PubMed  CAS  Google Scholar 

  70. Glueck CJ, Wang P, Fontaine R, et al.: Metformin to restore normal menstrual cycles in oligo-amenorrheic teenage girls with polycystic ovary syndrome. J Adolesc Health 2001, 29:160–169.

    Article  PubMed  CAS  Google Scholar 

  71. Legro RS: Detection of insulin resistance and its treatment in adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab 2002, 15(suppl 5):1367–1378.

    PubMed  CAS  Google Scholar 

  72. Kent SC, Legro RS: Polycystic ovary syndrome in adolescents. Adolesc Med 2002, 13:73–88.

    PubMed  Google Scholar 

  73. Kaufman FR: Type 2 diabetes mellitus in children and youth: a new epidemic. J Pediatr Endocrinol Metab 2002, 15(suppl 2):737–744.

    PubMed  Google Scholar 

  74. Nestler JE: Should patients with polycystic ovarian syndrome be treated with metformin?: an enthusiastic endorsement? Hum Reprod 2002, 17:1950–1953.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Jewish Hospital Cholesterol Center, ABC Building, 3200 Burnet Avenue, 45229, Cincinnati, OH, USA

    Charles J. Glueck MD, Naila Goldenberg MD, Patricia Streicher RD & Ping Wang PhD

Authors
  1. Charles J. Glueck MD
    View author publications

    Search author on:PubMed Google Scholar

  2. Naila Goldenberg MD
    View author publications

    Search author on:PubMed Google Scholar

  3. Patricia Streicher RD
    View author publications

    Search author on:PubMed Google Scholar

  4. Ping Wang PhD
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Glueck, C.J., Goldenberg, N., Streicher, P. et al. Metformin and gestational diabetes. Curr Diab Rep 3, 303–312 (2003). https://doi.org/10.1007/s11892-003-0022-0

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1007/s11892-003-0022-0

Keywords